Ken Maes

List of Publications by Year
in descending order

37 papers	1,311 citations	331538 21 h-index	360920 35 g-index
38 all docs	38 docs citations	38 times ranked	2425 citing authors

#	Article	IF	Citations
1	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Frontiers in Immunology, 2021, 12, 652160.	2.2	12
2	G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitorâ€“mediated cell death. Blood Advances, 2021, 5, 2325-2338.	2.5	19
3	Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo. Blood, 2021, 138, 1594-1594.	0.6	1
4	Therapeutic Efficacy of ²¹³Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer. Molecular Pharmaceutics, 2020, 17, 3553-3566.	2.3	34
5	Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2019, 7, 149.	1.8	5
6	AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma. Cancers, 2019, 11, 1727.	1.7	18
7	The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Frontiers in Genetics, 2019, 10, 740.	1.1	5
8	The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer, 2019, 120, 1137-1146.	2.9	12
9	Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal, 2019, 9, 87.	2.8	7
10	The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma. Cancers, 2019, 11, 1823.	1.7	36
11	Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters, 2019, 442, 233-241.	3.2	49
12	MCL1 Inhibitors in Multiple Myeloma. Blood, 2019, 134, SCI-12-SCI-12.	0.6	1
13	Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma. Blood, 2019, 134, 4335-4335.	0.6	0
14	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. British Journal of Cancer, 2018, 118, 1062-1073.	2.9	30
15	Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. Cancer Research, 2018, 78, 1155-1168.	0.4	27
16	Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal, 2018, 8, 105.	2.8	113
17	The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. Frontiers in Oncology, 2018, 8, 566.	1.3	39
18	The genetic landscape of 5T models for multiple myeloma. Scientific Reports, 2018, 8, 15030.	1.6	15

#	Article	IF	Citations
19	Metabolic Features of Multiple Myeloma. International Journal of Molecular Sciences, 2018, 19, 1200.	1.8	53
20	Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. OncoImmunology, 2018, 7, e1484981.	2.1	26
21	Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development. Blood, 2018, 132, 4484-4484.	0.6	3
22	Both mucosal-associated invariant and natural killer T-cell deficiency in multiple myeloma can be countered by PD-1 inhibition. Haematologica, 2017, 102, e266-e270.	1.7	28
23	Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunology Research, 2017, 5, 839-846.	1.6	41
24	The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget, 2017, 8, 90501-90520.	0.8	39
25	Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells. Oncotarget, 2017, 8, 52016-52025.	0.8	5
26	Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma. Oncotarget, 2016, 7, 38927-38945.	0.8	53
27	Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Letters, 2016, 377, 17-24.	3.2	106
28	Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget, 2016, 7, 6521-6537.	0.8	66
29	Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget, 2016, 7, 4062-4076.	0.8	33
30	The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget, 2016, 7, 48732-48752.	0.8	40
31	The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget, 2015, 6, 43992-44004.	0.8	127
32	<i>In vivo</i>treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma. Oncotarget, 2015, 6, 3319-3334.	0.8	25
33	Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment. Oncotarget, 2015, 6, 20621-20635.	0.8	17
34	The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma. Oncotarget, 2014, 5, 3115-3129.	0.8	48
35	The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic. Oncotarget, 2014, 5, 11193-11208.	0.8	15
36	Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma. Cancers, 2013, 5, 430-461.	1.7	43

#	Article	IF	Citations
37	In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood, 2010, 116, 3635-3644.	0.6	120